Jarrod M. Patten, a director at Strategy Inc, has reported a series of stock transactions in a recent SEC filing. This activity, which includes both the acquisition and disposition of shares, is significant for the company and the broader finance services sector, particularly as it relates to crypto assets.
Strategy Inc, based in Tysons Corner, Virginia, is involved in the finance services industry, specifically focusing on crypto assets. The company has undergone changes in its corporate identity, previously known as MicroStrategy Inc. The latest filing, dated November 4, 2026, reflects ongoing engagement by its director with the company's stock.
According to the filing, Patten executed transactions on November 3, 2026, involving 950 shares of Class A Common Stock. The transactions included an acquisition at a price of $18.236 per share and a disposition at a price of $136.040 per share. Following these transactions, Patten holds a total of 28,406 shares of Class A Common Stock and 10,000 shares of Series A Perpetual Strife Preferred Stock, among others.
The filing also reveals that Patten exercised stock options for 950 shares of Class A Common Stock at a conversion price of $18.236. This exercise reflects a strategic move, as the options vested in May 2020, indicating a long-term commitment to the company's performance.
This activity may affect various stakeholders, including investors and other directors within Strategy Inc. The filing underscores the importance of transparency in ownership changes and transactions, which can impact investor confidence and market perception.
As for what's next, the filing does not specify any upcoming events or additional filings related to these transactions. However, continued monitoring of Patten's activities may provide insights into the company's strategic direction in the finance services sector.
Read Next
Wassil Jim Reports Stock Transactions for Vaxcyte, Inc.
Cowan Elvia Reports Stock Transactions in SEC Filing
Saiki Julie Reports New Stock Transactions at Azora Therapeutics
Davidson Acquires Over 524,000 Shares of Azora Therapeutics
CBL & Associates Properties Announces New Stock Buyback Plan
Rothblatt amends Schedule 13G, reveals 4% stake in United Therapeutics









